RNA/DNA Polymerase

ART899 is a highly specific allosteric inhibitor of the DNA polymerase domain of polymerase theta (Polθ). It effectively enhances the radiosensitivity of tumor cells and demonstrates good tolerability when combined with fractionated radiation therapy. ART899 significantly reduces tumor growth compared to radiation alone, making it a promising candidate for combination cancer radiotherapy strategies.

Aphidicolin is a tetracyclic diterpenoid antibiotic produced by the mold Cephalosporium aphidicola, known for its potent and selective inhibition of DNA polymerase α and δ. By interfering with these polymerases, Aphidicolin blocks DNA synthesis and prevents mitotic cell division, making it a valuable tool for studying cell cycle regulation and DNA replication. In addition to its antiproliferative properties, Aphidicolin inhibits viral DNA synthesis and demonstrates antiviral activity against herpes simplex virus and orthopoxviruses. It also enhances apoptosis induced by arabinosyl nucleosides in human promyelocytic leukemia cells, suggesting potential in combination therapies for cancer and viral infections. Aphidicolin is widely used in research involving DNA replication stress, antiviral mechanisms, and cell cycle synchronization.

Foscarnet sodium, a viral DNA polymerase inhibitor, effectively suppresses viral replication through the reversible inhibition of polymerase activity. This compound is primarily utilized as an antiviral agent against herpesviruses, particularly in the treatment of cytomegalovirus retinitis. Its mechanism of action makes it a valuable tool for studying viral replication and evaluating therapeutic strategies against herpesvirus infections.

PD128763 is a selective inhibitor of poly(ADP-ribose) polymerase (PARP). This compound enhances the cytotoxic effects of Streptozotocin, making it a valuable tool for studying cellular mechanisms in leukemia. PD128763 is suitable for research applications focused on PARP-related pathways and therapeutic strategies in cancer treatment.

PNU-183792 is a potent inhibitor of herpes simplex virus (HSV) polymerases, classified as a 4-oxo-dihydroquinoline. It demonstrates broad-spectrum antiviral activity, exhibiting IC50 values of 0.69 μM for human cytomegalovirus (HCM), 0.37 μM for varicella zoster virus, and 0.58 μM for HSV polymerases. Importantly, PNU-183792 operates selectively, showing no activity against human α, γ, or δ polymerases. Additionally, it exhibits inhibitory effects on simian varicella virus (SVV), murine cytomegalovirus (MCMV), and rat cytomegalovirus (RCMV), making it a valuable tool for antiviral research.

Anti-infective agent 10 is an NS5B polymerase inhibitor designed for research into hepatitis C virus (HCV) infections. This compound effectively disrupts the viral replication process, making it a valuable tool for studying HCV biology and developing antiviral therapies. Its applications extend to evaluating drug resistance mechanisms and supporting drug discovery efforts in combating HCV.

HCV NS5B polymerase-IN-2 is an inhibitor targeting the NS5B polymerase of the hepatitis C virus (HCV). This compound demonstrates significant antiviral activity against HCV replication, making it a valuable tool for the investigation of hepatitis C viral infections and the development of therapeutic strategies. Its efficacy in inhibiting NS5B polymerase highlights its potential role in studying HCV dynamics and drug resistance.

BI 207524 is a selective non-nucleoside inhibitor of HCV NS5B polymerase, specifically targeting thumb pocket 1. This compound demonstrates antiviral activity against hepatitis C virus (HCV). BI 207524 is applicable in research focused on HCV infection and the mechanisms of antiviral response.

HCVP-IN-1 is a potent inhibitor of hepatitis C viral polymerase (HCVP). This compound effectively disrupts viral replication, making it a valuable tool for studying the dynamics of hepatitis C virus infection. HCVP-IN-1 is particularly relevant in research focused on developing antiviral therapies and understanding the mechanisms of HCV-related diseases.

RSV L-protein-IN-3 is an inhibitor of respiratory syncytial virus (RSV) polymerase, displaying an IC50 value of 10.4 μM and an EC50 value of 2.1 μM against RSV. It demonstrates reduced cytotoxicity compared to the clinical agent Ribavirin, making it a suitable candidate for further research into treating RSV infections. This compound is valuable for studies focusing on antiviral mechanisms and drug development targeting RSV.

RSV L-protein-IN-4 is a noncompetitive inhibitor of the respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 value of 0.88 μM. This compound demonstrates significant antiviral activity against various RSV strains, with an EC50 of 0.25 μM. RSV L-protein-IN-4 is essential for research into antiviral therapies targeting RSV infections.

RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms.

BPR3P0128 is a non-nucleoside inhibitor of RNA-dependent RNA polymerase (RdRp), demonstrating potent antiviral activity against various SARS-CoV-2 variants. It exhibits EC50 values of 0.62 μM for SARS-CoV-2 and 0.14 μM for HCoV-229E, effectively inhibiting virus replication within the submicromolar range. Additionally, BPR3P0128 shows synergistic effects when used in combination with Remdesivir, making it a promising candidate for further antiviral research against coronaviruses.

MB-11362 is a potent, orally active inhibitor of the hepatitis C virus (HCV) NS5B polymerase, functioning as a 4′-azidouridine triphosphate prodrug. Upon oral administration, MB-11362 is converted to its active form, 4′-azidouridine triphosphate, which effectively disrupts viral RNA synthesis. This compound is valuable for research focusing on HCV infection and understanding the mechanisms of antiviral therapies targeting RNA polymerases.

BILB 1941 is a potent nonnucleoside inhibitor targeting the hepatitis C virus (HCV) RNA polymerase. It demonstrates significant antiviral activity in vitro, making it a valuable tool for research applications related to HCV replication and drug development strategies against hepatitis C.

ABT-072 potassium trihydrate is a potent non-nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, exhibiting EC50 values of 1 nM against HCV genotype 1a and 0.3 nM against genotype 1b. This compound is primarily utilized in research focused on HCV replication and the development of antiviral therapies.

MK3281 is a non-nucleoside inhibitor targeting the hepatitis C virus (HCV) NS5B polymerase. It demonstrates significant antiviral activity, with an EC50 of 28 nM for genotype 1a. This compound is utilized in research focused on antiviral drug development and understanding HCV replication mechanisms.

PSI-353661 is a purine nucleotide inhibitor targeting the NS5B polymerase of Hepatitis C Virus (HCV). It demonstrates potent antiviral activity with EC90 values of 8 nM for wild-type HCV and 11 nM for the S282T resistant strain. Additionally, PSI-353661 achieves elevated levels of its active triphosphate form in primary human hepatocytes, making it a valuable tool for studying HCV replication and resistance mechanisms.

HCV NS5B polymerase-IN-3 is a potent inhibitor of the hepatitis C virus (HCV) NS5B polymerase, demonstrating significant antiviral activity. In the Huh7 replicon cell line, it exhibits an EC50 value of 0.23 μM while maintaining a favorable cytotoxicity profile. This compound is relevant for research applications focused on HCV replication and drug development strategies targeting hepatitis C.

VCH-916 free base is a non-nucleoside inhibitor targeting the NS5B polymerase of Hepatitis C virus (HCV). This compound demonstrates potent antiviral activity, making it a valuable tool for research on HCV replication. It is primarily utilized in studies focused on developing effective treatments for Hepatitis C and understanding the viral mechanisms of polymerase function.

GAP-1173149 is a selective inhibitor of the Chikungunya virus (CHIKV) polymerase, specifically targeting the nsP4 RNA-dependent RNA polymerase. This compound demonstrates potent antiviral activity by hindering viral RNA replication, making it a valuable tool for studying CHIKV biology and developing antiviral strategies. Its application is particularly relevant in research focused on emerging viral threats and potential therapeutic interventions for Chikungunya virus infections.

Cidofovir diphosphate is a potent inhibitor of viral DNA polymerases, primarily targeting human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), and herpes simplex virus type 2 (HSV-2). With Ki values of 6.6 μM, 0.86 μM, and 1.4 μM for these polymers, respectively, it demonstrates selective antiviral activity. This compound is instrumental in research focusing on antiviral drug development and elucidating the mechanisms underlying viral DNA replication.

T-1105 is a novel broad-spectrum viral polymerase inhibitor that acts by being converted into a ribonucleoside triphosphate (RTP) metabolite. This compound demonstrates antiviral activity against multiple RNA viruses by inhibiting their polymerases. T-1105 is particularly significant in studies aimed at understanding viral replication and developing antiviral strategies. Its mechanism of action highlights its potential applications in viral pathogenesis research and therapeutic interventions.

Troxacitabine triphosphate (TRX-TP) serves as a substrate for DNA polymerases, specifically targeting replicative and repair enzymes. This compound demonstrates key biological activity by facilitating DNA synthesis and repair processes in vitro. It is valuable for research applications that involve the study of nucleotide incorporation and polymerase activity, providing insights into DNA replication and repair mechanisms.